SCHEMBL5886256

SCHEMBL5886256

NC(=O)c1cccc2nc3ccc4ccccc4c3nc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.51
PARP1 P09874 11/20 0.49
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 2/20 0.46
PRMT5 O14744 1/20 0.46
PRMT3 O60678 1/20 0.46
CARM1 Q86X55 1/20 0.46
EHMT2 Q96KQ7 1/20 0.46
PRMT6 Q96LA8 1/20 0.46
PRMT1 Q99873 1/20 0.46
WDR77 Q9BQA1 1/20 0.46
POLB P06746 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GAA P10253 1/20 0.45
AURKA O14965 1/20 0.44
RPS6KB1 P23443 1/20 0.44
AURKB Q96GD4 1/20 0.44
PARP2 Q9UGN5 1/20 0.43
PARP3 Q9Y6F1 1/20 0.43
CD38 P28907 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886390 0.86 ALDH1A1 (0.68) RAD52ALDH1A1KDM4EPRMT5PRMT3
SCHEMBL10868710 0.85 ALDH1A1 (0.58) PARP1ALDH1A1PARP2PARP3IKBKB
SCHEMBL29611021 0.82 ALDH1A1 (0.70) PARP1ALDH1A1GAAPARP2PARP3
SCHEMBL818929 0.82 ALDH1A1 (0.70) PARP1ALDH1A1GAAPARP2PARP3
SCHEMBL5886293 0.81 ALDH1A1 (0.70) RAD52ALDH1A1KDM4ESMN1; SMN2
SCHEMBL5886447 0.81 KMT2A (0.54) RAD52ALDH1A1KDM4EGAA
SCHEMBL5473804 0.78 PRMT5 (0.59) ALDH1A1KDM4EPRMT5PRMT3CARM1
SCHEMBL28274572 0.78 ACHE (0.57) PARP1ALDH1A1KDM4EGAAPARP2
SCHEMBL10344430 0.77 ALDH1A1 (0.54) PARP1ALDH1A1KDM4EGAAAURKA
SCHEMBL7564139 0.76 PARP1 (0.53) PARP1ALDH1A1PARP2CD38

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7132419-B2 Pharmaceutical compounds XENOVA LIMITED (GB) 2006-11-07 US claimed
US-20050187172-A1 Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia PFIZER INC. 2005-08-25 US claimed
US-20050143383-A1 Pharmaceutical compounds XENOVA LIMITED (GB) 2005-06-30 US claimed
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LIMITED (GB) 2003-07-24 US claimed
EP-1240148-A1 BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II Xenova Limited (GB) 2002-09-18 EP claimed
WO-2001046157-A1 BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II XENOVA LIMITED (GB) 2001-06-28 WO claimed
CN-1304380-C Benzo[a]henazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LTD (GB) 2007-03-14 CN disclosed
CN-1304380-C Benzo[a]henazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LTD (GB) 2007-03-14 CN disclosed
US-7132419-B2 Pharmaceutical compounds XENOVA LIMITED (GB) 2006-11-07 US disclosed
US-7132419-B2 Pharmaceutical compounds XENOVA LIMITED (GB) 2006-11-07 US disclosed
US-20050187172-A1 Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia PFIZER INC. 2005-08-25 US disclosed
US-20050143383-A1 Pharmaceutical compounds XENOVA LIMITED (GB) 2005-06-30 US disclosed
US-20050143383-A1 Pharmaceutical compounds XENOVA LIMITED (GB) 2005-06-30 US disclosed
CN-1433406-A Benzo [ a ] phenazine-11-amide derivatives and their use as combined topoisomerase I and II inhibitors XENOVA LTD (GB) 2003-07-30 CN disclosed
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LIMITED (GB) 2003-07-24 US disclosed
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LIMITED (GB) 2003-07-24 US disclosed
EP-1240148-A1 BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II Xenova Limited (GB) 2002-09-18 EP disclosed
EP-1240148-A1 BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II Xenova Limited (GB) 2002-09-18 EP disclosed
WO-2001046157-A1 BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II XENOVA LIMITED (GB) 2001-06-28 WO disclosed
WO-2001046157-A1 BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II XENOVA LIMITED (GB) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143383-A1 Pharmaceutical compounds CHRNA10, OPRM1, SCN10A RAD52 2083/4885PARP1 4144/4885ALDH1A1 3766/4885
US-20050187172-A1 Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia TOP2A, TOP2B, TOP1 RAD52 52/4885PARP1 62/4885ALDH1A1 1202/4885
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II TOP1, TOP2A, TOP2B RAD52 60/4885PARP1 157/4885ALDH1A1 2334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.